About
OncoLattice Bio was built to help China-based oncology biotech sponsors make better U.S. clinical development decisions before entering costly CRO execution. Our role is to organize AI-enabled trial intelligence, RWD feasibility planning, and independent expert review into sponsor-facing decision memos.
Team
OncoLattice Bio is led across commercial strategy and technical development to support oncology sponsors with FIH planning, site diligence, competitor intelligence, and global development strategy. Team information is presented for company context and does not imply that any nonprofit institution provides commercial client services.
Chief Executive Officer / Head of Commercial Strategy and Partnerships
University of Waterloo alumnus responsible for company strategy, commercialization, client development, and strategic partnerships. At OncoLattice Bio, Zhipei focuses on translating site-level trial intelligence, competitor analysis, and China-to-global development needs into management-ready decision materials for oncology biotech sponsors, pharma BD teams, and strategic partners.
Chief Technology Officer / Medical AI Systems Lead
Physician-scientist and medical AI technology expert focused on AI medical systems, robotic surgery, oncology clinical applications, and real-world clinical workflows. Dr. Lun-Hsiang Yuan leads technology strategy, clinical intelligence methodology, data-product architecture, and platform quality boundaries so OncoLattice Bio's intelligence layer remains interpretable, reviewable, and useful for development decisions.
Commercial engagement, contracting, technical deployment, and expert participation are handled through OncoLattice Bio / AAI Inc. under appropriate governance and written authorization. The CTO profile is presented solely as an approved OncoLattice Bio commercial role.
Apex AI relationship
OncoLattice Bio is the commercial translation partner built to bring AI-native oncology trial intelligence into real-world drug development. The company operates independently as a commercial entity while leveraging technology and research foundations developed through the broader Apex AI ecosystem under appropriate licensing and governance structures.
Built on research foundations from the Apex AI ecosystem.
Supported by licensed AI infrastructure for commercial deployment through OncoLattice Bio / AAI Inc.
Structured to separate nonprofit research activities from commercial execution.
Expert governance
OncoLattice Bio references the broader Apex AI ecosystem as professional and research context only. Commercial engagements through OncoLattice Bio are separately governed, and any expert input requires explicit authorization, conflict review, and written approval.
View public Apex AI contextThe site references Apex AI context as a governed research foundation, not as a promise of direct nonprofit or individual client service.
Commercial projects are contracted and delivered through OncoLattice Bio / AAI Inc. under separate governance.
Expert input, where appropriate, is subject to authorization, conflict review, and written approval.
Apex AI references are for ecosystem context only. No current or former employer, nonprofit institution, or individual advisor is presented as endorsing OncoLattice Bio or participating in a commercial engagement unless separately authorized in writing.